help button home button Endocrine Society JCEM ENDO 08
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plockinger, U.
Right arrow Articles by Quabbe, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plockinger, U.
Right arrow Articles by Quabbe, H. J.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 1658-1662, Copyright © 1990 by Endocrine Society

ARTICLES

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

U Plockinger, D Dienemann and HJ Quabbe
Department of Internal Medicine, Freie Universitat, Berlin, Germany.

Gastrointestinal side-effects of prolonged therapy (greater than 2 yr) with the long-acting somatostatin analog octreotide were studied in 10 acromegalic patients. After 2 yr of therapy, 6 of 10 patients had newly developed gallstones, complicated by cholangitis and jaundice in 1. Serum vitamin B-12 concentrations declined in all 10 patients [from 380 +/- 32 to 172 +/- 21 pmol/L (mean +/- SE); P = 0.023] and became abnormally low in 4. Gastric biopsy specimens, obtained during gastroscopy (9 patients), showed moderate to severe active gastritis, with damage to the superficial and deeper layers of the mucosa in 9 of 9 and focal atrophy in 7 of 9 patients. Campylobacter pylori was found in the antral mucosa in 8 of 9 patients. Although information is lacking on similar studies in untreated acromegalic patients, we suggest that patients receiving chronic octreotide therapy be closely monitored for these and possible other side-effects related to gastrointestinal actions of octreotide.


This article has been cited by other articles:


Home page
 GutHome page
L A Thomas, M J Veysey, G M Murphy, D Russell-Jones, G L French, J A H Wass, and R H Dowling
Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly
Gut, May 1, 2005; 54(5): 630 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
G. I. Leontiadis, V. K. Sharma, and C. W. Howden
Non-Gastrointestinal Tract Associations of Helicobacter pylori Infection: What Is the Evidence?
Arch Intern Med, May 10, 1999; 159(9): 925 - 940.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Rubin, J. Ajani, W. Schirmer, A. P. Venook, R. Bukowski, R. Pommier, L. Saltz, P. Dandona, and L. Anthony
Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
J. Clin. Oncol., February 1, 1999; 17(2): 600 - 600.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society